Nano Science and Technology Institute

Arrowhead Subsidiary, Insert Therapeutics, to Present at NSTI Nanotech 07 Conference

Dr. Thomas Schluep, CSO, will present at the Nanotech for Investors Summit at the NSTI Nanotech 2007 Conference on May 21, 2007 in Santa Clara, California.

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Dr. Thomas Schluep, Chief Scientific Officer of Insert Therapeutics, a majority owned subsidiary of Arrowhead, will present at the Nanotech for Investors Summit at the Nano Science and Technology Institute 2007 Conference on May 21, 2007 in Santa Clara, California. Dr. Schlueps presentation, entitled Insert Therapeutics Product Development Update, will highlight Inserts technical and clinical progress in using its proprietary polymeric transport system, CyclosertTM, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Inserts lead drug candidate, a combination of its linear, cyclodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.

Dr. Schluep is responsible for Inserts drug discovery and development programs. Prior to joining Insert in 2004, Dr. Schluep was in charge of the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary of Schering-Plough. While at Canji, he held multiple positions of increasing responsibility in the development, manufacture, and analytical testing of non-viral and adenoviral gene therapy vectors. A constant interest of Dr. Schluep has been to understand the role nanotechnology can play in enhancing the efficacy and therapeutic index of a wide variety of therapeutics. He holds a Sc.D. in Process Engineering and an MS in Biotechnology, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Insert Therapeutics

Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Inserts affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


 
© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map